These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19929694)

  • 1. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.
    Asmuth DM; Brown EL; DiNubile MJ; Sun X; del Rio C; Harro C; Keefer MC; Kublin JG; Dubey SA; Kierstead LS; Casimiro DR; Shiver JW; Robertson MN; Quirk EK; Mehrotra DV
    J Infect Dis; 2010 Jan; 201(1):132-41. PubMed ID: 19929694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
    Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
    Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
    Harro CD; Robertson MN; Lally MA; O'Neill LD; Edupuganti S; Goepfert PA; Mulligan MJ; Priddy FH; Dubey SA; Kierstead LS; Sun X; Casimiro DR; DiNubile MJ; Shiver JW; Leavitt RY; Mehrotra DV;
    AIDS Res Hum Retroviruses; 2009 Jan; 25(1):103-14. PubMed ID: 19108693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
    Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR
    Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
    Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
    J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
    Asefa B; Korokhov N; Lemiale F
    Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
    Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K
    Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
    Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
    J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
    Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
    J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
    Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
    Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
    Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
    PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.